Evidence map›Paper›PMID 26564142›Full record

ArticleJournal of computer-aided molecular design2015

Mappability of drug-like space: towards a polypharmacologically competent map of drug-relevant compounds.

Pavel Sidorov, Helena Gaspar, Gilles Marcou, Alexandre Varnek, Dragos Horvath

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of computer-aided molecular design, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Rings in Clinical Trials and Drugs: Present and Future.Journal of medicinal chemistry · 2022
    Review
  6. DMSO Solubility Assessment for Fragment-Based Screening.Molecules (Basel, Switzerland) · 2021
    Article
  7. Article
  8. Article
  9. Article
  10. Diversifying chemical libraries with generative topographic mapping.Journal of computer-aided molecular design · 2020
    Article
  11. Article
  12. Multi-task generative topographic mapping in virtual screening.Journal of computer-aided molecular design · 2019
    Article
  13. Enhanced taxonomy annotation of antiviral activity data from ChEMBL.Database : the journal of biological databases and curation · 2019
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. QSAR modeling and chemical space analysis of antimalarial compounds.Journal of computer-aided molecular design · 2017
    Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Pavel SidorovLaboratoire de Chémoinformatique, UMR 7140, CNRS-Univ. Strasbourg, 1 rue Blaise Pascal, 67000, Strasbourg, France.
Helena GasparLaboratoire de Chémoinformatique, UMR 7140, CNRS-Univ. Strasbourg, 1 rue Blaise Pascal, 67000, Strasbourg, France.
Gilles MarcouLaboratoire de Chémoinformatique, UMR 7140, CNRS-Univ. Strasbourg, 1 rue Blaise Pascal, 67000, Strasbourg, France.
Alexandre VarnekLaboratoire de Chémoinformatique, UMR 7140, CNRS-Univ. Strasbourg, 1 rue Blaise Pascal, 67000, Strasbourg, France.
Dragos HorvathLaboratoire de Chémoinformatique, UMR 7140, CNRS-Univ. Strasbourg, 1 rue Blaise Pascal, 67000, Strasbourg, France. dhorvath@unistra.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intuitive, visual rendering--mapping--of high-dimensional chemical spaces (CS), is an important topic in chemoinformatics. Such maps were so far dedicated to specific compound collections--either limited series of known activities, or large, even exhaustive enumerations of molecules, but without associated property data. Typically, they were challenged to answer some classification problem with respect to those same molecules, admired for their aesthetical virtues and then forgotten--because they were set-specific constructs. This work wishes to address the question whether a general, compound set-independent map can be generated, and the claim of "universality" quantitatively justified, with respect to all the structure-activity information available so far--or, more realistically, an exploitable but significant fraction thereof. The "universal" CS map is expected to project molecules from the initial CS into a lower-dimensional space that is neighborhood behavior-compliant with respect to a large panel of ligand properties. Such map should be able to discriminate actives from inactives, or even support quantitative neighborhood-based, parameter-free property prediction (regression) models, for a wide panel of targets and target families. It should be polypharmacologically competent, without requiring any target-specific parameter fitting. This work describes an evolutionary growth procedure of such maps, based on generative topographic mapping, followed by the validation of their polypharmacological competence. Validation was achieved with respect to a maximum of exploitable structure-activity information, covering all of Homo sapiens proteins of the ChEMBL database, antiparasitic and antiviral data, etc. Five evolved maps satisfactorily solved hundreds of activity-based ligand classification challenges for targets, and even in vivo properties independent from training data. They also stood chemogenomics-related challenges, as cumulated responsibility vectors obtained by mapping of target-specific ligand collections were shown to represent validated target descriptors, complying with currently accepted target classification in biology. Therefore, they represent, in our opinion, a robust and well documented answer to the key question "What is a good CS map?"

Indexed as

Computer GraphicsAntiparasitic AgentsAntiviral AgentsDatabases, PharmaceuticalDrug DiscoveryHumansLigandsParasitic DiseasesPolypharmacologyProteinsStructure-Activity RelationshipVirus DiseasesAntiparasitic AgentsAntiviral AgentsLigandsProteinsChemical space mappingGenerative topographic mapsPolypharmacologyStructure–property relationships

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.